CASI Pharmaceuticals, Inc. (CASI) Institutional Ownership

Based on Q2 2025 13F filings, institutional ownership of CASI Pharmaceuticals, Inc. stands at 0.0%, held across 1 reporting institutions.

CONCOURSE FINANCIAL GROUP SECURITIES, INC. is the largest reported institutional holder of CASI, with approximately 0 shares worth $0.00B as of Q2 2025.

No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of CASI.

Our composite Smart Money Score for CASI is 37 out of 100 (Bearish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

0 institutions opened new positions in CASI during Q2 2025, while 0 fully exited. 0 added to existing positions and 0 trimmed.

CASI institutional ownership rose by 0.00 percentage points quarter-over-quarter, with a net change of +0 holders.

The top 10 institutions account for 0.0% of all reported 13F value in CASI, and the top 25 account for 0.0%.

All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.